163 related articles for article (PubMed ID: 30370535)
21. Clinical Value and Prospective Pathway Signaling of MicroRNA-375 in Lung Adenocarcinoma: A Study Based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Bioinformatics Analysis.
Gan TQ; Chen WJ; Qin H; Huang SN; Yang LH; Fang YY; Pan LJ; Li ZY; Chen G
Med Sci Monit; 2017 May; 23():2453-2464. PubMed ID: 28533502
[TBL] [Abstract][Full Text] [Related]
22. Aberrant Methylation and Differential Expression of SLC2A1, TNS4, GAPDH, ATP8A2, and CASZ1 Are Associated with the Prognosis of Lung Adenocarcinoma.
Wang X; Shi D; Zhao D; Hu D
Biomed Res Int; 2020; 2020():1807089. PubMed ID: 33029490
[TBL] [Abstract][Full Text] [Related]
23. LncRNA DGCR5 promotes lung adenocarcinoma (LUAD) progression via inhibiting hsa-mir-22-3p.
Dong HX; Wang R; Jin XY; Zeng J; Pan J
J Cell Physiol; 2018 May; 233(5):4126-4136. PubMed ID: 29030962
[TBL] [Abstract][Full Text] [Related]
24. CircRNA has_circ_0006427 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/β-catenin signaling pathway.
Yao Y; Hua Q; Zhou Y
Biochem Biophys Res Commun; 2019 Jan; 508(1):37-45. PubMed ID: 30470570
[TBL] [Abstract][Full Text] [Related]
25. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
26. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of DNA methylation and microRNA regulation of the lung adenocarcinoma transcriptome.
Du J; Zhang L
Oncol Rep; 2015 Aug; 34(2):585-94. PubMed ID: 26035298
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation biomarkers for the occurrence of lung adenocarcinoma from TCGA data mining.
Zhu XF; Zhu BS; Wu FM; Hu HB
J Cell Physiol; 2018 Oct; 233(10):6777-6784. PubMed ID: 29667778
[TBL] [Abstract][Full Text] [Related]
29. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract][Full Text] [Related]
30. High
Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
[TBL] [Abstract][Full Text] [Related]
31. Low expression of LINC00982 and PRDM16 is associated with altered gene expression, damaged pathways and poor survival in lung adenocarcinoma.
Lv W; Yu X; Li W; Feng N; Feng T; Wang Y; Lin H; Qian B
Oncol Rep; 2018 Nov; 40(5):2698-2709. PubMed ID: 30132554
[TBL] [Abstract][Full Text] [Related]
32. Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma.
Brativnyk A; Ankill J; Helland Å; Fleischer T
Int J Cancer; 2024 Jul; 155(2):282-297. PubMed ID: 38489486
[TBL] [Abstract][Full Text] [Related]
33. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.
Yerukala Sathipati S; Ho SY
Sci Rep; 2017 Aug; 7(1):7507. PubMed ID: 28790336
[TBL] [Abstract][Full Text] [Related]
34. microRNA-1205 promotes cell growth by targeting APC2 in lung adenocarcinoma.
Dai B; Kong DL; Tian J; Liu TW; Zhou H; Wang ZF
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1125-1133. PubMed ID: 30779081
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of LncRNA-UCA1 Correlates with Lung Adenocarcinoma Progression and Poor Prognosis.
Chen L; Cao P; Wu Q; Guo Y; Yang Y; Chen F
Clin Lab; 2019 Mar; 65(3):. PubMed ID: 30868851
[TBL] [Abstract][Full Text] [Related]
36. Methyl-CpG Binding Domain Protein 2 Inhibits the Malignant Characteristic of Lung Adenocarcinoma through the Epigenetic Modulation of 10 to 11 Translocation 1 and miR-200s.
Pei YF; Xu XN; Wang ZF; Wang FW; Wu WD; Geng JF; Liu XQ
Am J Pathol; 2019 May; 189(5):1065-1076. PubMed ID: 30735628
[TBL] [Abstract][Full Text] [Related]
37. DNA methylation-based diagnostic and prognostic biomarkers of nonsmoking lung adenocarcinoma patients.
Zhang X; Gao C; Liu L; Zhou C; Liu C; Li J; Zhuang J; Sun C
J Cell Biochem; 2019 Aug; 120(8):13520-13530. PubMed ID: 30920015
[TBL] [Abstract][Full Text] [Related]
38. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
39. Identification of differential protein-coding gene expressions in early phase lung adenocarcinoma.
Zhou LN; Li SC; Li XY; Ge H; Li HM
Thorac Cancer; 2018 Feb; 9(2):234-240. PubMed ID: 29266838
[TBL] [Abstract][Full Text] [Related]
40. Integrated whole-exome and bulk transcriptome sequencing delineates the dynamic evolution from preneoplasia to invasive lung adenocarcinoma featured with ground-glass nodules.
Zhou D; Li YQ; Liu QX; Deng XF; Chen L; Li MY; Zhang J; Lu X; Zheng H; Dai JG
Cancer Med; 2024 Jun; 13(11):e7383. PubMed ID: 38864483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
